Company History and Chronology
Greystone Pharmaceuticals Inc.
Greystone Pharmaceuticals Inc. was founded in 1996 by Gregory P. Pilant to investigate and commercialize new wound-healing technologies - both natural and synthetic - and license them for distribution.
1995
A wound treatment made from botanical oak bark extract.
2001
More than five years and millions of dollars later, Greystone Pharmaceuticals Inc. isolates the active ingredients in the botanical formulation that are responsible for wound healing. Soon after, Greystone Pharmaceuticals Inc. begins a series of scientific and clinical studies in Europe to investigate the mechanism of action of the products and to test their efficacy and safety in human subjects.
2002
DerMax® is approved as a Class IIa medical device in the EU. After the submission of additional clinical and scientific data, DerMax® is reclassified as a Class IIb medical device. DerMax® is launched in 21 countries.
2005
Epi-Max® is cleared for sale in the United States by the FDA as a combination product governed by the medical device regulation 510(k).
MelMax® is launched in Europe and the Middle East.
2008
Greystone Pharmaceuticals Inc. signed a multi-national License Agreement with 3M.
2009
Greystone Pharmaceuticals Inc. reorganized and the operations of all the assets of the Company were awarded to
Presidia Pharmaceuticals.
2012
The Wound Care Co. LLC was formed to undertake all the order globally.
2012
The Asian office for the Companies was formed.
2014
The new generation of the technology was developed, and a new patent was filled.
2014
Accellerex was approved for sale in Taiwan.
